SCHEMBL4835994

SCHEMBL4835994

Nc1nc(Cl)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@@]3(O)F)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.56
LMNA P02545 3/20 0.48
TP53 P04637 2/20 0.48
NT5E P21589 2/20 0.46
CYP2C19 P33261 1/20 0.45
ADORA3 P0DMS8 4/20 0.45
ADORA1 P30542 4/20 0.45
ADORA2B P29275 2/20 0.45
ADA P00813 1/20 0.45
ALOX15 P16050 1/20 0.45
PDE4D Q08499 2/20 0.44
PDE3A Q14432 2/20 0.44
SLC29A1 Q99808 2/20 0.44
PDE2A O00408 1/20 0.44
ADRA1A P35348 1/20 0.44
PGK1 P00558 1/20 0.43
PGK2 P07205 1/20 0.43
PNP P00491 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8713052 0.90 ADORA2A (0.54) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL16777303 0.89 ADORA2A (0.53) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL19107854 0.89 ADORA2A (0.53) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL16777213 0.89 ADORA2A (0.53) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL1888832 0.89 ADORA2A (0.61) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL4839727 0.89 ADORA2A (0.61) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL15679246 0.88 ADORA2A (0.58) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL11896637 0.88 ADORA2A (0.58) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL29148201 0.88 ADORA2A (0.58) ADORA2ALMNATP53NT5ECYP2C19
SCHEMBL30679282 0.88 ADORA2A (0.58) ADORA2ALMNATP53NT5ECYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7381820-B2 α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside YAMASA CORPORATION (JP) 2008-06-03 US disclosed
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside KOHEL YAMADA, ETAL 2007-06-14 US disclosed
EP-1676853-A1 ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E YAMASA CORPORATION (JP) 2006-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside TYMP, PNP, DUT ADORA2A 314/4885LMNA 2519/4885TP53 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.